- Published at
- by manilatimes.net
mixed
mixed
News for Alexion Pharmaceuticals, Inc. (ALXN)
- Published at
- by markets.businessinsider.com
mixedmixedTeva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States
EPYSQLI ® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, at...- Published at
- by gurufocus.com
positivepositiveViridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines fo- Published at
- by gurufocus.com
positivepositiveCamber Capital Management LLC's Strategic Acquisition in ZimVie Inc
On December 31, 2024, Camber Capital Management LLC (Trades, Portfolio) executed a significant transaction by acquiring 2,722,987 shares of ZimVie Inc at a trad- Published at
- by gurufocus.com
positivepositiveCamber Capital Management LLC's Strategic Acquisition of PTC Therapeutics Inc Shares
On December 31, 2024, Camber Capital Management LLC (Trades, Portfolio) executed a noteworthy transaction by acquiring 3,197,987 shares of PTC Therapeutics Inc.- Published at
- by rttnews.com
mixedmixedMonopar's Incredible Journey From $5 To $50 In Less Than 5 Months
From the brink of Nasdaq delisting last year due to non-compliance with the minimum bid price rule, this clinical-stage biotechnology company has made a remarkable comeback.- Published at
- by gurufocus.com
neutralneutralSamsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and- Published at
- by investing.com
mixedmixedNovel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab By Investing
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab- Published at
- by gurufocus.com
positivepositiveLabcorp Holdings Inc. (LH) Announces Executive Leadership Transition
Labcorp Holdings Inc. (LH) has announced a significant change in its executive leadership team. On November 15, 2024, Glenn Eisenberg, the company's Executive- Published at
- by investing.com
mixedmixedCertara adds pharmaceutical veteran to board By Investing.com
Certara adds pharmaceutical veteran to board- Published at
- by globenewswire.com
mixedmixedOrphan Drugs Market Size & Share to Surpass USD 424.0 billion by 2034, Rising a CAGR 6.9% | Analysis by Transparency Market Research, Inc.
An increase in the prevalence and misdiagnosis of rare diseases has led to an increase in the sales of orphan drugs....JNJIDP.DEDJNJ3.BADJNJ2.BABIIBD.BABIIBCL.SNBIIB.SNBIIB.MXBIIB.BABIIBAMGN.MXAMGN.BAAMGNAMG.DENVSN.MXNVSEFNVSD.BANVSNOVN.SWN1VS34.SADSNKYDSKYF4568.T0K9E.LZEG.DEPFED.BAPFECL.SNPFE.SNPFE.MXPFE.DEPFENVON.MXNVONOVOBN.MXNOVC.DENOVA.DENONOFMRKD.BAMRK.SNMRK.PAMRK.MXMRKLLY.MXLLY.DELLY.BALLYLILY34.SAGSK.LGSKGS7.DEGLAXFESALYESALFBRM.DEBMYB34.SABMY.MXBMY.BABMYAZNN.MXAZNCFAZN.LAZNAXP.DEALXN6MK.DE4523.T0TDD.L0QZM.L0Q1G.L0A4J.L- Published at
- by globenewswire.com
mixedmixedCassava Sciences Names Rick Barry as Chief Executive Officer
Claude Nicaise, M.D. appointed Chairman of the Board...- Published at
- by globenewswire.com
mixedmixedEliem Therapeutics Announces Additions to its Leadership Team
Brett Kaplan, M.D. appointed Chief Operating Officer Nishi Rampal, M.D. appointed Senior Vice President, Clinical Development SEATTLE and CAMBRIDGE,...- Published at
- by seekingalpha.com
mixedmixedQuince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex (NASDAQ:QNCX)
Quince’s transformation is complete with the acquisition of EryDel in October 2023. Check out the reasons why I rate QNCX stock as a Strong Buy.- Published at
- by globenewswire.com
mixedmixedAvalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
WAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Mittie Doyle, MD, FACR has...- Published at
- by investing.com
mixedmixedPharmaEssentia Promotes Robert B. Geller, M.D. to General Manager By Investing.com
PharmaEssentia Promotes Robert B. Geller, M.D. to General Manager- Published at
- by globenewswire.com
positivepositiveVerve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of...- Published at
- by investing.com
mixedmixed- Published at
- by globenewswire.com
mixedmixedRare Diseases market is projected to grow at a CAGR of 8.8% by 2034: Visiongain
Visiongain has published a new report entitled Rare Diseases Market Report 2024-2034: Forecasts by Diseases (Cancer, Metabolic Diseases, Neurological...NVSN.MXNVSEFNVSD.BANVSNOVN.SWN1VS34.SAABBV34.SAABBV.MXABBV.BAABBV4AB.DE0K9E.LVX1.DEVRTX34.SAVRTX.MXVRTXTKPHFTAKP34.SATAKN.MXTAKIDP.DEBIIBD.BABIIBCL.SNBIIB.SNBIIB.MXBIIB.BABIIBAXP.DEAMGN.MXAMGN.BAAMGNAMG.DEALXN4502.T4502.S0QZU.L0QZM.L0A87.LPFED.BAPFECL.SNPFE.SNPFE.MXPFE.DEPFEMRKD.BAMRK.SNMRK.PAMRK.MXMRKJNJDJNJ3.BADJNJ2.BABRM.DEBMYB34.SABMY.MXBMY.BABMY6MK.DE- Published at
- by marketscreener.com
mixedmixedAchilles Therapeutics : THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION
THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, please seek your own financial advice from...